More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL

Collegeville, Pennsylvania (ots/PRNewswire) -

- Wyeth Withdraws European Application

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced
today that it is withdrawing its application for an extension to the
European Marketing Authorization for TYGACIL(R) (tigecycline). This
extension sought approval of TYGACIL for the treatment of
community-acquired pneumonia (CAP). Wyeth's action is based on its
understanding of the Committee for Medicinal Products for Human Use
(CHMP) assessment that the TYGACIL CAP pivotal clinical trials did
not include a sufficient number of severely ill CAP patients to
alleviate reviewer concerns regarding efficacy in this subpopulation.
TYGACIL is currently approved in Europe for the treatment of
complicated intra-abdominal infections and complicated skin and soft
tissue infections in adults.

"We are disappointed that we were not able to allay the concerns
of the CHMP, and are evaluating the appropriate next steps to take in
Europe," says Gary L. Stiles, M.D., Executive Vice President and
Chief Medical Officer, Wyeth Pharmaceuticals. "In October 2007, the
U.S. Food and Drug Administration (FDA) accepted the filing of our
supplemental New Drug Application for TYGACIL for the treatment of
patients with CAP. We believe that the clinical trial data submitted
to the FDA, as well as other regulatory authorities around the world,
demonstrate the safety and efficacy of TYGACIL for the proposed CAP
indication."

The FDA is currently reviewing this application and a decision is
expected during the second quarter of 2008. TYGACIL has been approved
for use in patients with CAP in the Philippines and Thailand.
Regulatory applications are also pending in Australia, Brazil,
Canada, Switzerland and India.

Indications
TYGACIL(R) (tigecycline) is indicated for the treatment of adults with:
-- Complicated skin and skin structure infections caused by Escherichia
coli, Enterococcus faecalis (vancomycin-susceptible isolates only),
Staphylococcus aureus (methicillin-susceptible and -resistant
isolates), Streptococcus agalactiae, Streptococcus anginosus group
(includes S. anginosus, S. intermedius, and S. constellatus),
Streptococcus pyogenes, and Bacteroides fragilis
-- Complicated intra-abdominal infections caused by Citrobacter freundii,
Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella
pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates
only), Staphylococcus aureus (methicillin-susceptible isolates only),
Streptococcus anginosus group (includes S. anginosus, S. intermedius,
and S. constellatus), Bacteroides fragilis, Bacteroides
thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus,
Clostridium perfringens, and Peptostreptococcus micros
Important Safety Information
-- To reduce the development of drug-resistant bacteria and maintain the
effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should
be used only to treat infections proven or strongly suspected to be
caused by susceptible bacteria
-- Anaphylaxis/anaphylactoid reactions have been reported with nearly all
antibacterial agents, including tigecycline, and may be life-
threatening
-- TYGACIL is contraindicated in patients with known hypersensitivity to
tigecycline
-- TYGACIL should be administered with caution in patients with known
hypersensitivity to tetracycline class antibiotics
-- Glycylcycline class antibiotics are structurally similar to
tetracycline class antibiotics and may have similar adverse effects.
Such effects may include: photosensitivity, pseudotumor cerebri, and
anti-anabolic action (which has led to increased BUN, azotemia,
acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis
has been reported with the use of TYGACIL
-- The safety and efficacy of TYGACIL in patients with hospital-acquired
pneumonia have not been established
-- In clinical trials, the most common treatment-emergent adverse events
in patients treated with TYGACIL were nausea (29.5%) and vomiting
(19.7%)
-- TYGACIL may cause fetal harm when administered to a pregnant woman
-- The safety and effectiveness of TYGACIL in patients below age 18 and
lactating women have not been established
-- Clostridium difficile-associated diarrhea (CDAD) has been reported with
use of nearly all antibacterial agents, including TYGACIL, and may
range in severity from mild diarrhea to fatal colitis
-- Concurrent use of antibacterial drugs with oral contraceptives may
render oral contraceptives less effective
-- The use of TYGACIL during tooth development may cause permanent
discoloration of the teeth. TYGACIL should not be used during tooth
development unless other drugs are not likely to be effective or are
contraindicated
-- Prothrombin time or other suitable anticoagulant test should be
monitored if TYGACIL is administered with warfarin
-- Monotherapy should be used with caution in patients with clinically
apparent intestinal perforation
-- In patients with severe hepatic impairment (Child Pugh C), the initial
dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours.
Patients should be treated with caution and monitored for treatment
response
-- The following drugs should not be administered simultaneously through
the same Y-site as TYGACIL: amphotericin B and diazepam

Please see Prescribing Information.

Wyeth Pharmaceuticals:

Wyeth Pharmaceuticals, a division of Wyeth has leading products
in the areas of women's health care, infectious disease,
gastrointestinal health, central nervous system, inflammation,
transplantation, hemophilia, oncology, vaccines and nutritional
products.

Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies. It is a leader in
the discovery, development, manufacturing and marketing of
pharmaceuticals, vaccines, biotechnology products, nutritionals and
non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.

The statements in this press release that are not historical
facts are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, without limitation, the inherent uncertainty
of the timing and success of, and expense associated with, research,
development, regulatory approval and commercialization of our
products and pipeline products; government cost-containment
initiatives; restrictions on third-party payments for our products;
substantial competition in our industry, including from branded and
generic products; emerging data on our products and pipeline
products; the importance of strong performance from our principal
products and our anticipated new product introductions; the highly
regulated nature of our business; product liability, intellectual
property and other litigation risks and environmental liabilities;
uncertainty regarding our intellectual property rights and those of
others; difficulties associated with, and regulatory compliance with
respect to, manufacturing of our products; risks associated with our
strategic relationships; economic conditions including interest and
currency exchange rate fluctuations; changes in generally accepted
accounting principles; trade buying patterns; the impact of
legislation and regulatory compliance; risks and uncertainties
associated with global operations and sales; and other risks and
uncertainties, including those detailed from time to time in our
periodic reports filed with the Securities and Exchange Commission,
including our current reports on Form 8-K, quarterly reports on Form
10-Q and annual report on Form 10-K, particularly the discussion
under the caption "Item 1A, Risk Factors" in our Annual Report on
Form 10-K for the year ended December 31, 2007, which was filed with
the Securities and Exchange Commission on February 29, 2008. The
forward-looking statements in this press release are qualified by
these risk factors. We assume no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.

Web site: http://www.wyeth.com

ots Originaltext: Wyeth Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Contacts: Sal Foti, Wyeth Pharmaceuticals, +1-484-865-3490, or
Douglas Petkus, Wyeth, +1-973-660-5218; or Investor Contact: Justin
Victoria, Wyeth, +1-973-660-5340